New progress in the study of protein kinase C(PKC)inhibitors
10.11958/20150079
- VernacularTitle:蛋白激酶C抑制剂的研究新进展
- Author:
Jing WU
;
Rui YANG
;
Shuye LIU
- Publication Type:Journal Article
- Keywords:
protein kinase C;
enzyme inhibitors;
trypsin inhibitors;
protein kinase inhibitors;
neoplasms;
review
- From:
Tianjin Medical Journal
2016;44(1):114-117
- CountryChina
- Language:Chinese
-
Abstract:
Protein kinase C (PKC) is a group of phospholipid-dependent serine/threonine protein kinases, which togeth-er with protein kinase A (PKA) and protein kinase G (PKG) constitute a superfamily of serine/threonine protein kinase AGC. PKC includes classic PKC, novel PKC, atypical PKC and some members of kinase associated with PKC (PRK). PKC is wide-ly distributed in mammalian tissues and cells, which plays an important biological role in growth and metabolism, prolifera-tion and differentiation of cells. A series of studies have demonstrated that variations of multiple cells, occurrence and devel-opment of diseases are related to the abnormal expression of PKC. Therefore, designing and searching for efficient PKC inhib-itors have very important implications for synthesis of many kinds of effective drugs and treatment of a variety of clinical dis-eases including cancer, cardiovascular, and hypertension, et al. In recent years, the research on PKC inhibitors has become the focus of domestic and foreign research. A large number of literatures have reported many kinds of effective PKC inhibi-tors, and analyzed their function site, mechanism, clinical trial data and so on. The discovery of these PKC inhibitors has im-portant implications for structural analysis of PKC and the treatment of diseases. So in this paper, the efficient PKC inhibi-tors are summarized.
